Benefits
Abdominal discomfort, bloating and bowel habits
In adults with IBS, 2 billion CFU daily for 8 weeks lowered abdominal pain and raised complete bowel movements more than placebo, and in 141 children with IBS, chewable tablets for 8 weeks lowered pain scores more than placebo. A strain-specific pooled analysis of these two trials supported the effect, with high variability. Both trials were run with the maker.
Stool frequency and consistency
In 100 adults with functional constipation, 2 billion CFU daily for 4 weeks raised bowel movements more than placebo. In 144 healthy adults with infrequent bowel movements, stool consistency improved versus placebo, mainly through fewer hard stools, but stool frequency, the main outcome, was not shown to beat placebo. A meta-analysis found no significant rise in stool frequency for pooled trials of this strain.
Blood amino acids from daily whey protein
In resistance-trained young men taking 20 g of whey protein daily for 60 days, adding 2 billion CFU raised total plasma free amino acids by 16.1% and branched-chain amino acids by 33.1% versus whey alone. These are blood markers. The authors also report higher leg-press strength and jump power, from a single trial with maker co-authors.
Mouth bacteria counts in children
In 48 children aged 5 to 15 at higher risk of tooth decay, a 2 billion CFU chewable tablet for 14 days lowered streptococci and lactobacilli counts in saliva and plaque from baseline; on placebo, streptococci did not change and lactobacilli rose. These are bacterial counts rather than tooth outcomes, the main tests compared each group with its own baseline, and the maker funded the study.
Stress-related behavior in animal research
In rats exposed to early separation and chronic stress, 6 weeks of this strain in drinking water reduced anxiety- and depression-like behavior and shifted gut bacteria and fecal short-chain fatty acids. This is animal work only. No human trial of the strain alone has tested mood or stress.
Mechanism of action
Hardy spores that pass the stomach
Bacillus coagulans forms dormant spores. The strain's draft genome, published by maker researchers, includes about 92 genes for sporulation and dormancy and 84 for stress response, and earlier lab work cited there describes tolerance of heat and stomach acid. How many spores germinate in the human gut has not been measured in the cited trials.
Lactic acid and other fermentation products
The species ferments sugars into lactic acid, and the strain's genome carries many carbohydrate-use genes and two putative bacteriocin operons. A constipation trial linked symptom relief to the strain's ability to make short-chain fatty acids, and in stressed rats the strain restored fecal acetate, propionate and butyrate levels. Direct human measurements are lacking.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Bacillus coagulans strain Unique IS2, 2 billion CFU daily for 8 weeks, after a 2-week placebo run-in, at two Mumbai sites (CTRI/2017/07/009170); fully funded by Unique Biotech (Madempudi et al. 2019, Sci Rep).
136 adults aged 18 to 60 meeting Rome III criteria for IBS, randomized after a run-in that excluded non-compliant participants; 108 completed and were analyzed.
Both primary outcomes, abdominal pain intensity and complete spontaneous bowel movements, improved more than with placebo: pain fell from 8.2 to 3.4 versus 8.3 to 6.7 on a 0 to 10 scale (p < 0.001), and weekly complete bowel movements rose from 2.5 to 4.0 versus 2.2 to 2.4, with 79% versus 40% meeting the bowel movement response (p < 0.001). Secondary symptoms also improved; blood inflammatory markers did not change. Results were reported for the 108 completers only, after 28 of 136 dropped out. Three authors are employees of the strain's maker.
Double-blind, randomized, placebo-controlled trial of Unique IS2 chewable tablets or placebo once daily for 8 weeks, then a 2-week follow-up. A later paper by the maker gives the dose as 2 billion CFU (Sudha et al. 2018, Benef Microbes).
141 children aged 4 to 12 with IBS by Rome III criteria.
Pain scores fell more with the probiotic than with placebo by week 8 (7.6 versus 4.2 points, P < 0.0001), and stool consistency, abdominal discomfort, bloating, straining, urgency, incomplete evacuation, gas, bowel habit satisfaction and global relief improved more. The abstract names no single primary outcome and does not state funding, and the first two authors work for Unique Biotech.
Double-blind, placebo-controlled trial of Unique IS2, 2 billion CFU or placebo capsules once daily for 4 weeks (CTRI/2017/11/010539) (Madempudi et al. 2020, Probiotics Antimicrob Proteins).
100 adults diagnosed with functional constipation.
Treatment success was defined as three or more spontaneous stools a week, but the abstract does not report how many reached it or state funding. Bowel movements increased more than with placebo (p < 0.001), 98% reached normal stool consistency versus 74% on placebo, and incomplete evacuation, painful defecation and abdominal pain eased more. Three authors work for Unique Biotech, the maker.
Randomized, double-blind, placebo-controlled trial of Bacillus coagulans strain Unique IS2, 2 billion CFU/day for 4 weeks after a 2-week run-in (NCT05123664) (LeMoire et al. 2025, Benef Microbes).
144 healthy adults averaging 3 to fewer than 7 complete bowel movements per week.
Bowel movement frequency, the registered primary outcome, rose from baseline in the probiotic group (p = 0.037), but the abstract gives no placebo comparison for it, and press coverage of the trial reports that the difference from placebo was not significant. Stool consistency improved more than with placebo (p = 0.018), mainly through fewer hard stools (p = 0.001). There was no effect on GI symptoms, quality of life, gut microbiota or the share of complete bowel movements. PepsiCo sponsored the trial, and three co-authors work there.
Double-blind, placebo-controlled trial: 20 g whey protein daily with 2 billion CFU Unique IS-2 or with lactose placebo for 60 days alongside a controlled resistance-training program (CTRI/2017/03/008117) (Tarik et al. 2022, Eur J Nutr).
Resistance-trained men averaging 21 years old.
Total plasma free amino acids rose 16.1% (p = 0.004), and branched-chain amino acids were 33.1% higher than with placebo at 60 days. The authors also report a probiotic effect on leg-press 1RM (+16.6%, p = 0.024) and vertical jump power (+7.9%, p = 0.007), among several strength, muscle size, VO2 max and body composition measures. One trial; the abstract does not state funding, and two co-authors are from the strain's maker.
Double-blind, randomized, placebo-controlled trial of a 2 billion CFU Unique IS2 chewable tablet or placebo tablet once daily for 14 days at a dental school (CTRI/2017/07/009072); funded by Unique Biotech, which made both tablets (Ratna Sudha et al. 2020, Int J Dent).
48 children aged 5 to 15 at higher risk of tooth decay (DMFS/defs score of 5 or more; 24 per group), all of whom completed the study.
The primary measure, mutans streptococci in saliva and plaque, fell from baseline in the probiotic group (salivary score 3.86 to 2.56, p < 0.001) and did not change on placebo, though the probiotic group started higher. Lactobacilli also fell, while they rose on placebo. Saliva and plaque pH did not change. Tests were mainly within-group, and caries itself was not measured. Two authors work for the maker.
Randomized, double-blind, placebo-controlled, three-arm trial: standard care plus Unique IS-2 or Bacillus clausii UBBC-07 oral suspension (2 billion spores twice daily) or water placebo for 14 days (CTRI/2021/03/031720); products supplied by Unique Biotech, and authors report no funding (Ali Mirza et al. 2024, Cureus).
56 hospitalized adults with moderate COVID-19, about 18 to 19 per arm, all given remdesivir; analysis per protocol.
Clinical recovery, oxygen saturation, breathing rate and progression to severe disease did not differ between groups. Serum ferritin fell more than with placebo, and D-dimer fell more by day 14; CRP, LDH and IL-6 did not differ. These are blood markers from a small trial, and the probiotic is not a treatment for any infection.